These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 16149296)
61. Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days. Bearz A; Vaccher E; Spazzapan S; Berretta M; Tirelli U Lung Cancer; 2005 Sep; 49(3):417-8. PubMed ID: 16102608 [No Abstract] [Full Text] [Related]
62. Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib. Zhang XT; Li LY; Wang SL; Mu XL; Wang MZ; Song W Chin Med J (Engl); 2005 Oct; 118(19):1661-4. PubMed ID: 16232354 [No Abstract] [Full Text] [Related]
63. KL-6 and poor prognosis in NSCLC patients treated with gefitinib. Ohara G; Kurishima K; Ishikawa H; Satoh H; Hizawa N Lung Cancer; 2008 Jan; 59(1):138; author reply 139. PubMed ID: 18006181 [No Abstract] [Full Text] [Related]
65. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488 [TBL] [Abstract][Full Text] [Related]
66. Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. Marko-Varga G; Fehniger TE; Rezeli M; Döme B; Laurell T; Végvári A J Proteomics; 2011 Jun; 74(7):982-92. PubMed ID: 21440690 [TBL] [Abstract][Full Text] [Related]
67. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial? Johnson DH; Arteaga CL J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243 [No Abstract] [Full Text] [Related]
68. Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease. Yuan MK; Chang CY; Chang SC; Chang SJ; Tang GJ; Wei YF; Liu YC; Chen CY; Yu CJ Int J Clin Pharmacol Ther; 2011 Oct; 49(10):587-93. PubMed ID: 21961483 [TBL] [Abstract][Full Text] [Related]
69. Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer. Garfield DH Lung Cancer; 2006 Nov; 54(2):259. PubMed ID: 16935393 [No Abstract] [Full Text] [Related]
70. APL during gefitinib treatment for non-small-cell lung cancer. Uchida A; Matsuo K; Tanimoto M N Engl J Med; 2005 Feb; 352(8):843. PubMed ID: 15728826 [No Abstract] [Full Text] [Related]
71. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Comis RL Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313 [No Abstract] [Full Text] [Related]
72. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097 [TBL] [Abstract][Full Text] [Related]
73. [Non-small-cell lung cancer third-line therapy with gefitinib]. Fischer JR; Haffner U; Dietrich GM; Spahlinger B; Geiger D; Lahm H Pneumologie; 2005 May; 59(5):321-7. PubMed ID: 15902597 [TBL] [Abstract][Full Text] [Related]
74. Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer. Iurisci I; Rich T; Lévi F; Innominato PF; Tinari N; Irtelli L; De Tursi M; Grassadonia A; Iacobelli S J Clin Oncol; 2007 Jun; 25(16):e17-9. PubMed ID: 17538154 [No Abstract] [Full Text] [Related]
75. EGFR mutations and sensitivity to gefitinib. Sorscher SM N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15371587 [No Abstract] [Full Text] [Related]
76. Clinical efficacy and toxiciy of gefitinib in patients with lung cancer. Mitsui H; Nakajima J; Maruyama T; Hanajiri K; Omata M Lancet; 2003 Jun; 361(9373):1993. PubMed ID: 12801776 [No Abstract] [Full Text] [Related]